 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 2 | 1/1 | 返回列表 |
| 查看: 620 | 回復: 1 | ||
| 本帖產生 1 個 翻譯EPI ，點擊這里進行查看 | ||
霜葉金蟲 (小有名氣)
|
[求助]
翻譯一段摘要，非常感謝
|
|
|
Abstract Purpose To assess the e cacy and toxicity of an oralY anticancer uoropyrimidine derivative, S-1, for previouslyX treated patients with advanced non-small cell lung cancer (NSCLC). Patients and methods Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6weeks. Results Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% con dence intervalW (95%CI), 3.1–21.9%). Disease control rate was 39.6% (19/ 48) (95%CI, 25.7–53.4%). Median progression-free sur- vival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxici- ties comprised neutropenia in one patient (2.1%) and ane- mia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only ve patients (10.4%).W Treatment-related death did not occur. Conclusion S-1 is an active and well-tolerated mono- therapy for second-line treatment of advanced NSCLC. [ Last edited by 霜葉 on 2013-2-27 at 10:32 ] |
回復此樓» 猜你喜歡
【求調劑】085601材料工程專碩 | 總分272 |
已經有5人回復
-
275求調劑
已經有13人回復
-
0856，材料與化工321分求調劑
已經有8人回復
-
085701環(huán)境工程，267求調劑
已經有12人回復
-
320分，材料與化工專業(yè)，求調劑
已經有7人回復
-
085701環(huán)境工程求調劑
已經有8人回復
-
295材料工程專碩求調劑
已經有5人回復
-
265求調劑
已經有8人回復
-
322求調劑
已經有4人回復
-
085602 307分 求調劑
已經有6人回復
【答案】應助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
phu_grassman: 金幣+20, 翻譯EPI+1, thanks for your time and energy 2013-03-01 13:42:02
phu_grassman: 金幣+20, 翻譯EPI+1, thanks for your time and energy 2013-03-01 13:42:02
|
摘要 目的 評估口服抗癌藥物（S-1）的有效性和毒性，這種藥用于晚期非小細胞肺癌(NSCLC)患者的前期治療。 患者和方法 患者是先前接收過一次鉑化療的晚期非小細胞肺癌患者。病人連續(xù)28天口服s – 1，劑量通過使用基于病人的BSA做的列線圖所確定，每6周重復一次。 結果 2005年8月至2007年7月,50個患者參與本研究。6個病人有部分反應(PR), 且符合條件的患者整體反應率為12.5%(6/48) (95%置信區(qū)間,3.1 -21.9%)。疾病控制率為39.6% (19/48) (95% 置信區(qū)間,25.7 -53.4%)。平均無進展存活時間是2.5個月。平均存活時間是8.2個月,1年的生存率為29.6%。沒有遇到4級毒性反應。中性粒細胞減少造成的三級血液毒性患者(2.1%)和貧血各1例(2.1%)。5個病人出現(xiàn)三級非血液毒性 (10.4%)。沒有發(fā)生與治療相關的死亡。 結論 s - 1是一種有效的和藥物單一治療具有良好耐受性的晚期非小細胞肺癌二線治療藥物。 本人水平有限，希望能幫到你。  |
2樓2013-03-01 12:45:41
相關版塊跳轉
我要訂閱樓主 霜葉 的主題更新
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 275求調劑 +10 | Micky11223 2026-03-25 | 13/650 |
|
|---|---|---|---|---|
|
|
[考研] 340求調劑 +4 | jhx777 2026-03-27 | 4/200 |
|
|
|
[考研] 328求調劑 +6 | 嗯滴的基本都 2026-03-27 | 6/300 |
|
|
|
[考研] 材料與化工（0856）304求B區(qū)調劑 +7 | 邱gl 2026-03-27 | 7/350 |
|
|
[考研] 269專碩求調劑 +10 | 金恩貝 2026-03-21 | 10/500 |
|
|
|
[考研] 0703一志愿9，初試成績：338，四六級已過，有科研經歷，求調劑！ +3 | Zuhui0306 2026-03-25 | 3/150 |
|
|
|
[考研] 305求調劑 +5 | 哇盧卡庫 2026-03-26 | 5/250 |
|
|
|
[考研] 考研調劑 +10 | 呼呼？~+123456 2026-03-24 | 10/500 |
|
|
|
[考研] 334求調劑 +3 | 雨清天晴 2026-03-21 | 3/150 |
|
|
|
[考研] 0856材料專碩353求調劑 +9 | NIFFFfff 2026-03-20 | 9/450 |
|
|
|
[考研] 材料調劑 +8 | 匹克i 2026-03-23 | 8/400 |
|
|
|
[考研] 316求調劑 +5 | 江辭666 2026-03-26 | 5/250 |
|
|
|
[考研] 071000生物學求調劑，初試成績343 +6 | 小小甜面團 2026-03-25 | 6/300 |
|
|
|
[考研] 求調劑 +8 | Auroracx 2026-03-22 | 8/400 |
|
|
|
[考研] 生物學學碩，一志愿湖南大學，初試成績338 +4 | YYYYYNNNNN 2026-03-26 | 4/200 |
|
|
|
[考研] 化學調劑一志愿上海交通大學336分-本科上海211 +4 | 小魚愛有機 2026-03-25 | 4/200 |
|
|
|
[考研] 一志愿天津大學339材料與化工求調劑 +3 | 江往賣魚 2026-03-26 | 3/150 |
|
|
|
[考研] 299求調劑 +7 | 某某某某位 2026-03-21 | 8/400 |
|
|
|
[考研] 284求調劑 +3 | yanzhixue111 2026-03-23 | 6/300 |
|
|
|
[考研] 生物學一志愿985，分數(shù)349求調劑 +6 | zxts12 2026-03-21 | 9/450 |
|